The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...

Universal CAR T cells produce rapid remissions and enable allogeneic stem cell transplants in patients with relapsed or refractory T-cell acute lymphoblastic leukemia.

As the immune system weakens with age, scientists have found a way to restore some of its lost strength. By delivering mRNA ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, ...

In this interview Shahzad Raza, MD, highlights data on CAR T-cell therapies and the use of bispecifics in earlier lines of multiple myeloma as presented at ASH 2025.

In this interview, Ann S. LaCasce, MD, highlights a late-breaking abstract on in vivo CAR T-cell therapy use in multiple myeloma, as presented at ASH 2025.

Despite a Trump administration push, there are few facilities offering the complex treatment in the rural areas where many ...

MIT researchers are using living cells to target diseased brain areas and deliver tiny electronic devices that can modulate ...

It has been claimed that because most of our DNA is active, it must be important, but now human-plant hybrid cells have been ...

Understanding how cells decide their fate is a central challenge in biology, complicated by the fact that single-cell RNA ...